Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 15, 2018 16:15 ET | Source: Ascendis Pharma A/S

Ascendis Pharma A/S Announces Second Quarter 2018 Financial Results and Business Update Conference Call on August 29

COPENHAGEN, Denmark, Aug. 15, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet...
August 02, 2018 07:00 ET | Source: Ascendis Pharma A/S

Ascendis Pharma A/S Announces Participation in the 2018 Wedbush PacGrow Healthcare Conference

COPENHAGEN, Denmark, Aug. 02, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet...
July 23, 2018 16:44 ET | Source: Ascendis Pharma A/S

Ascendis Pharma A/S Announces Poster Presentation on TransCon Technology at the Controlled Release Society Annual Meeting

COPENHAGEN, Denmark, July 23, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet...
June 06, 2018 17:35 ET | Source: Ascendis Pharma A/S

Ascendis Pharma Announces Orphan Drug Designation Granted for TransCon PTH as Treatment for Hypoparathyroidism

COPENHAGEN, Denmark, June 06, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet...
May 30, 2018 16:02 ET | Source: Ascendis Pharma A/S

Ascendis Pharma A/S Reports First Quarter 2018 Financial Results

- Continued execution and achievement of planned milestones across three wholly-owned clinical programs in rare endocrine diseases - - Conference Call Today at 4:30 p.m. Eastern Time - COPENHAGEN,...
May 16, 2018 16:20 ET | Source: Ascendis Pharma A/S

Ascendis Pharma A/S Announces First Quarter 2018 Financial Results and Business Update Conference Call on May 30

COPENHAGEN, Denmark, May 16, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet...
May 08, 2018 07:00 ET | Source: Ascendis Pharma A/S

Ascendis Pharma A/S Announces Dosing of First Subjects in Phase 1 Trial of TransCon CNP

- TransCon CNP is Company’s Third Product Candidate in Clinic - COPENHAGEN, Denmark, May 08, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes...
May 07, 2018 16:05 ET | Source: Ascendis Pharma A/S

Ascendis Pharma A/S Announces Poster Presentation on TransCon PTH Phase 1 Trial at the European Congress of Endocrinology

COPENHAGEN, Denmark, May 07, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet...
April 25, 2018 08:30 ET | Source: Ascendis Pharma A/S

Ascendis Pharma A/S Announces Upcoming Investor Presentations

COPENHAGEN, Denmark, April 25, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a clinical stage biopharmaceutical company that applies its innovative TransCon technology to address...
April 02, 2018 08:30 ET | Source: Ascendis Pharma A/S

Ascendis Pharma A/S Appoints Thomas A. Larson as Chief Commercial Officer

COPENHAGEN, Denmark, April 02, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a clinical stage biopharmaceutical company that applies its innovative TransCon technology to address...